Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma
NCT05055323Phase 1Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Jul 2021
- Primary completion
- Aug 2024
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrvinium in pancreatic ductal adenocarcinoma (PDAC), sponsored by Thomas Jefferson University. Primary endpoint: Incidence of dose limited toxicity at 30 days. Started Jul 2021; status: active, not recruiting.
02
Drugs
pyrvinium
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05055323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055323.